Literature DB >> 11421371

Hepatitis C in Peru: risk factors for infection, potential iatrogenic transmission, and genotype distribution.

J L Sanchez1, M H Sjogren, J D Callahan, D M Watts, C Lucas, M Abdel-Hamid, N T Constantine, K C Hyams, S Hinostroza, R Figueroa-Barrios, J C Cuthie.   

Abstract

A large seroepidemiologic and genotyping study of hepatitis C virus (HCV) was conducted in Lima, Peru, during the periods of 1986 to 1993 (cohort A) and 1994 (cohort B). Anti-HCV seroprevalence rates were 15.6% (216 of 1,389) and 11.7% (168 of 1,438), respectively. Low rates were seen among volunteer blood donors (1.1% and 0.8%). Anti-HCV rates were much higher among patients undergoing hemodialysis (43.7% and 59.3%), hemophiliacs (60.0% and 83.3%), in those more than 39 years old (18.2% and 26.0%), in females (25.0% and 27.4%), and in less-educated persons (16.9%). Age- and gender-adjusted risk factors in cohort B included blood transfusion history (adjusted odds ratio [AOR] = 29.8), prior organ transplantation (AOR = 9.1) or a history of hepatitis (AOR = 4.9), previous hospitalization (AOR = 3.7), a history of intravenous drug use (AOR = 3.5), prior major surgery (AOR = 2.6), a history of acupuncture (AOR = 2.1), previous dental procedures (AOR = 1.2), and prior medical injections (AOR = 1.04). The most prevalent HCV genotype was type 1 (86%), followed by type 3 (10%) and type 2 (2%). Transmission through unsafe injection-related and medical/dental procedures appears to play an important role in HCV infection among Peruvians.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11421371

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  11 in total

1.  Prevalence and risk factors for hepatitis C infection in rural north Vietnam.

Authors:  Van Thi Thuy Nguyen; Mary-Louise McLaws; Gregory J Dore
Journal:  Hepatol Int       Date:  2007-07-19       Impact factor: 6.047

2.  Hepatitis C virus infection in infants and children from Argentina.

Authors:  María Inés Gismondi; Estela Inés Turazza; Saúl Grinstein; María Cristina Galoppo; María Victoria Preciado
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

3.  A shield against a monster: Hepatitis C in hemodialysis patients.

Authors:  Seyed-Moayed Alavian
Journal:  World J Gastroenterol       Date:  2009-02-14       Impact factor: 5.742

Review 4.  Management of hepatitis C virus infection in hemodialysis patients.

Authors:  Yue-Cheng Yu; Yue Wang; Chang-Lun He; Mao-Rong Wang; Yu-Ming Wang
Journal:  World J Hepatol       Date:  2014-06-27

5.  Lack of evidence of hepatitis C and HIV co-infection among men who have sex with men in Peru.

Authors:  Javier R Lama; Aldo Lucchetti; Cesar Cabezas; Luis Suarez-Ognio; Jorge Sanchez
Journal:  Am J Trop Med Hyg       Date:  2009-07       Impact factor: 2.345

6.  Infection by the hepatitis C virus in chronic renal failure patients undergoing hemodialysis in Mato Grosso state, central Brazil: a cohort study.

Authors:  Marcelo A M Santos; Francisco J D Souto
Journal:  BMC Public Health       Date:  2007-03-12       Impact factor: 3.295

Review 7.  Viral hepatitis in hemodialysis: An update.

Authors:  Bassam Bernieh
Journal:  J Transl Int Med       Date:  2015-09-30

8.  Molecular characterization of hepatitis c virus in multi-transfused Colombian patients.

Authors:  Diana di Filippo; Fabian Cortes-Mancera; Mauricio Beltran; Maria Patricia Arbelaez; Sergio Jaramillo; Juan Carlos Restrepo; Gonzalo Correa; Maria-Cristina Navas
Journal:  Virol J       Date:  2012-10-23       Impact factor: 4.099

9.  Hepatitis B and C in dialysis units in Kosova.

Authors:  Skender Telaku; Hajrullah Fejza; Ymer Elezi; Teuta Bicaj
Journal:  Virol J       Date:  2009-06-04       Impact factor: 4.099

10.  Sexual behavior and drug consumption among young adults in a shantytown in Lima, Peru.

Authors:  Juan A Gálvez-Buccollini; Suzanne DeLea; Phabiola M Herrera; Robert H Gilman; Valerie Paz-Soldan
Journal:  BMC Public Health       Date:  2009-01-19       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.